A Phase 3 interventional study of KP-100IT in Acute Spinal Cord Injury (SCI), sponsored by Kringle Pharma, Inc.. Not yet recruiting at 3 sites in Japan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Kringle Pharma, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.
Kringle Pharma, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KP-100IT
The contents of each vial were dissolved in the distilled water for injection, and the study drug (0.6 mg as KP-100) was administered intrathecally once per week a total of 5 times.
Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administration, 24 weeks
Time frame: 24 weeks after investigational product administration
Time course of ASIA motor score (total/ upper extremity / lower upper extremity)
Time frame: From baseline through 24 weeks
Time course of ASIA sensory score
Time frame: From baseline through 24 weeks
Time course of AIS classification
Time frame: From baseline through 24 weeks
Time course of modified Frankel classification
Time frame: From baseline through 24 weeks
Time course of neurological level of injury
Time frame: From baseline through 24 weeks
Percentage of subjects improving by at least 5 and 10 points on the ASIA motor score at 12 weeks and 24 weeks after administration relative to before study drug administration
Time frame: 12 weeks and 24 weeks after investigational product administration
Time courses of plasma concentration and cerebrospinal fluid concentration of KP-100 after intrathecal administration
Time frame: From dosing through 24weeks
Evaluation of adverse events
Time frame: From the first drug administration through the end of the observation period (24 weeks)
Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KP-100IT
Deafness, Autosomal Recessive 39
Kringle Pharma, Inc.